BioAtla, Inc.BCABNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating

Buy

9 analysts·Limited coverage

67%

Rating Distribution

Strong Buy

00%

Buy

667%

Hold

333%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 2546% higher.

Bear Case

$5.00

+2546%

Consensus

$5.00

+2546%

Bull Case

$5.00

+2546%

Price Range9 analysts

Low

Consensus

High

$5.00

Current Target

Current Price

$0.19

Upside to Target

$4.81

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.92(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-81.73%

EPS—

FY2028

Rev+1416.67%

EPS—

FY2029

Rev+338.46%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+10.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

May 23, 2024JMP Securities

BioAtla price target lowered to $5 from $12 at JMP Securities

Target:$5.00

+119.3%from $2.28

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance